Neb Obradovic
@Cormorant Asset Management, Lp
Latest period2024 - Q3ReportedManaged Assets$1.886BTotal holdings45
Assets growth rate8.94%Assets growth rate (2-Q avg)-7.56%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Cormorant Asset Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 45 positions.
Assets under management
The assets under management (AUM) of Cormorant Asset Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.886B in assets, with a quarterly growth rate of 8.94% and a 2-quarter average growth rate of -7.56%. The portfolio is managed by Neb Obradovic, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
EWTXEdgewise Therapeutics Inc
| 4.83% | $90.92M 3.407M shares@ $26.69 avg price | Increased 13.31% |
RAPPRapport Therapeutics Inc
| 3.2% | $60.23M 2.941M shares@ $20.48 avg price | Increased 0.03% |
PRAXPraxis Precision Medicines I
| 2.66% | $50.06M 870,000 shares@ $57.54 avg price | Increased 27.01% |
CRBPCorbus Pharmaceuticals Hldgs
| 2.6% | $48.996M 2.375M shares@ $20.63 avg price | Increased 17.29% |
RNAAvidity Biosciences Inc
| 2.56% | $48.226M 1.05M shares@ $45.93 avg price | Increased 147.06% |
NAMSNewamsterdam Pharma Company
| 2.18% | $41.002M 2.47M shares@ $16.6 avg price | Increased 7.4% |
CNTACentessa Pharmaceuticals Plc
| 2.18% | $40.96M 2.562M shares@ $15.99 avg price | Increased 58.95% |
AVBPArrivent Biopharma Inc
| 0.73% | $13.758M 585,462 shares@ $23.5 avg price | Increased 13.69% |